Zyversa Therapeutics Inc (ZVSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 102 | 528 | 72 | 1,612 | 1,531 |
| Other current assets | 15 | 169 | 98 | 0 | 0 |
| TOTAL | $348 | $996 | $549 | $2,110 | $1,716 |
| Non-Current Assets | |||||
| Intangibles | 0 | 0 | 18,648 | 18,648 | 18,648 |
| Other Non-Current Assets | 0 | 45 | 444 | 227 | 236 |
| TOTAL | $N/A | $45 | $19,092 | $18,875 | $18,884 |
| Total Assets | $348 | $1,040 | $19,641 | $20,986 | $20,599 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 10,123 | 9,805 | 9,774 | 9,605 | 9,337 |
| Accrued Expenses | 2,611 | 2,961 | 2,915 | 2,399 | 1,894 |
| TOTAL | $12,735 | $12,766 | $12,690 | $12,004 | $11,231 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $852 | $852 | $852 |
| Total Liabilities | $12,735 | $12,766 | $13,541 | $12,855 | $12,083 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 8,096 | 8,096 | 8,096 | 4,773 | 2,568 |
| Common Shares | 1 | 1 | 1 | 0 | 0 |
| Retained earnings | -137,585 | -136,906 | -117,101 | -114,890 | -112,633 |
| Other shareholders' equity | -7 | -7 | -7 | -7 | -7 |
| TOTAL | $-12,387 | $-11,726 | $6,100 | $8,130 | $8,516 |
| Total Liabilities And Equity | $348 | $1,040 | $19,641 | $20,986 | $20,599 |